Berenberg has initiated coverage of BioNTech (BNTX) and Moderna (MRNA), citing their leadership positions in mRNA medicine.

Berenberg analyst Harry Gillis initiated coverage of Moderna (MRNA) with a Hold rating and $42 price target. The firm says mRNA will ...

API technology startup Kong Inc. said today it has closed on a bumper $175 million late-stage round of funding, bringing its ...

Leerink Partners analyst Mani Foroohar has reiterated their bearish stance on MRNA stock, giving a Sell rating on November 14.Don't Miss our ...

The S&P 500 added 0.4% on Monday, Nov. 18, kicking off a trading week that will feature a highly anticipated earnings report ...

Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

Shares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to ...

CNBC's Jim Cramer reports on the latest news regarding Moderna. 'Mad Money' host Jim Cramer looks at the recent move down in ...

Kennedy Jr. to head the U.S. Department of Health and Human Services makes a good entry point for investors, according to Piper Sandler. Piper Sandler, which reiterated Overweight rating on Moderna, ...

Pfizer's stock dropped 4.3 percent while Moderna's fell 3.1 percent and Novavax saw a 2.8 percent dip in its stock Friday ...

( NewsNation) — Shares in some pharmaceutical and biotechnology companies, including those that manufacture vaccines, fell ...

If you missed the early fall push for flu and COVID-19 vaccines, it’s not too late. Health officials say it’s important to ...